Short Interest in Enzo Biochem, Inc. (NYSE:ENZ) Declines By 6.9%

Enzo Biochem, Inc. (NYSE:ENZ) was the recipient of a significant drop in short interest during the month of June. As of June 15th, there was short interest totalling 560,500 shares, a drop of 6.9% from the May 31st total of 602,300 shares. Currently, 1.6% of the shares of the stock are short sold. Based on an average daily trading volume, of 114,700 shares, the short-interest ratio is presently 4.9 days.

Enzo Biochem Trading Down 3.6 %

ENZ traded down $0.04 during trading hours on Tuesday, hitting $1.07. The company’s stock had a trading volume of 24,984 shares, compared to its average volume of 109,882. The business’s 50-day moving average price is $1.10 and its 200-day moving average price is $1.23. Enzo Biochem has a 12 month low of $0.99 and a 12 month high of $1.89.

Institutional Investors Weigh In On Enzo Biochem

An institutional investor recently bought a new position in Enzo Biochem stock. FNY Investment Advisers LLC acquired a new position in shares of Enzo Biochem, Inc. (NYSE:ENZ) in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund acquired 75,911 shares of the medical research company’s stock, valued at approximately $105,000. FNY Investment Advisers LLC owned 0.15% of Enzo Biochem as of its most recent SEC filing. Hedge funds and other institutional investors own 36.90% of the company’s stock.

About Enzo Biochem

Enzo Biochem, Inc develops, manufactures, and markets products and tools for clinical research, translational research, drug development, and bioscience research customers worldwide. The company offers proteins, antibodies, peptides, small molecules, labeling probes, dyes, and kits, which provide life science researchers tools for target identification/validation, content analysis, gene expression analysis, nucleic acid detection, protein biochemistry and detection, and cellular analysis.